Quipt Home Medical (QIPT) Proxy Filing summary

Executive summary

• Shareholders are being asked to approve an arrangement where all outstanding common shares will be acquired for $3.65 per share in cash, subject to certain conditions and regulatory approvals.

• The arrangement is expected to be completed in the first half of 2026, pending satisfaction or waiver of all conditions.

• Shareholders must submit a properly completed Letter of Transmittal and supporting documents to receive payment.

• Payment can be made in U.S. dollars or, upon election, in Canadian dollars at the prevailing exchange rate, with all currency conversion risks borne by the shareholder.

• Shareholders who do not submit required documents within six years of the effective date forfeit their right to receive payment.

Voting matters and shareholder proposals

• Approval of the arrangement will be considered at a special meeting of shareholders scheduled for March 3, 2026.

• Voting is separate from the submission of the Letter of Transmittal; shareholders must vote in person or by proxy.

Related party transactions

• The arrangement involves the acquisition of all outstanding shares by a designated purchaser, with all rights, dividends, and distributions assigned to the purchaser at the effective time.